Scienture Holdings, Inc. — filing identity
The supplied filing is a Form 10-Q for Trxade Group, Inc., not Scienture Holdings, Inc. It reports the quarter ended March 31, 2019, with unaudited comparisons to the three months ended March 31, 2018. The company operates a pharmaceutical marketplace and also has wholesale, specialty-pharmacy, and delivery-software businesses.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / prior balance-sheet date |
|---|---|---|
| Revenue | $1,512,521 | $852,923 |
| Gross profit | $1,146,682 | $852,923 |
| Gross margin | 75.8% | 100.0% as presented |
| Operating expenses | $974,923 | $754,195 |
| Operating income | $171,759 | $98,728 |
| Net income | $125,229 | $82,269 |
| Operating cash flow | $(125,794) | $66,663 |
| Cash, March 31 / December 31 | $533,929 | $869,557 |
| Working capital, March 31 / December 31 | $682,943 | $605,710 |
Revenue increased about 77% year over year; management attributes the rise to the Community Specialty Pharmacy acquisition and higher Trxade platform revenue. Cost of sales was $365,839, whereas none was reported for the 2018 quarter, so the gross-margin comparison is not like-for-like. Basic and diluted earnings per share were each reported as $0.00.
Total assets were $3.30 million and total liabilities $2.08 million at March 31. Current liabilities were $808,448. Debt included $140,000 of related-party convertible notes due in July and August 2019 and $522,552 of related-party long-term notes. Lease liabilities totaled $829,528, of which $79,072 was current. Cash fell by $335,628 during the quarter, primarily reflecting the $210,000 SyncHealth investment; receivables also increased by $295,169 and contributed to operating cash use.
Material changes and significant transactions
- Community Specialty Pharmacy, acquired in October 2018, contributed $442,423 of Q1 2019 revenue. The company reported $1,043,810 from Trxade, $26,288 from Other, and a $28,972 equity-method loss from SyncHealth.
- In February 2019, $211,983 of principal and accrued interest on older convertible notes was converted into 423,966 common shares. The company also issued 16,666 shares upon warrant exercise. Common shares outstanding rose to 33,726,489 at quarter-end.
- The company invested $250,000 for an interest in SyncHealth MSO; $210,000 was paid by March 31 and the remaining $40,000 in April. The filing describes Alliance’s current ownership as 30%, while also describing staged transfers of additional interests and an option to acquire the remaining 51%, in exchange for company shares subject to stated revenue quotas.
- Adoption of lease accounting on January 1, 2019 resulted in recognition of right-of-use assets and lease obligations. The balance sheet recorded $825,697 in right-of-use assets.
Outlook, risks, and controls
Management identified continued platform development, customer growth, and increased operating revenue as 2019 priorities. It estimated 2019 general and administrative and working-capital requirements at approximately $3.5 million and said additional capital would be needed. Management expected to pursue financing but cautioned that operating cash generation and access to financing on acceptable terms were not assured; equity financing could dilute shareholders and borrowing would increase liabilities and cash commitments. No specific revenue or earnings guidance was provided.
The filing reports no outstanding off-balance-sheet arrangements and no legal proceedings. Management stated disclosure controls and procedures were not effective at quarter-end; it reported no material change in internal control over financial reporting during the quarter. Risk factors were stated to be unchanged from the company’s prior annual report. April and May subsequent events included grants of 505,000 options, with exercise prices reported in the notes as $0.41 to $0.44; specified grants went to directors and senior officers.
Important facts for investors to verify
- Confirm the issuer: the provided filing identifies Trxade Group, Inc., despite the request metadata naming Scienture Holdings, Inc.
- Reconcile inconsistent presentation within the filing: the statements report Q1 2019 general and administrative expense of $974,923, while MD&A gives $938,944 before separately listing $35,979 of warrant and option expense. The equity rollforward also shows $126,229 for net income in one row, versus $125,229 elsewhere.
- Review the SyncHealth ownership-transfer schedule, share consideration range, revenue-quota conditions, and the accounting for the investment and associated losses.
- Assess near-term funding needs against the $533,929 quarter-end cash balance, negative operating cash flow, related-party note maturities, and stated financing uncertainty.
- Evaluate the implications of ineffective disclosure controls and the dilution potential from outstanding warrants, options, and planned SyncHealth share transfers.